Samir K. Gupta, MD, MS
Potential Financial Conflicts of Interest: Dr. Gupta has received advisory and speaking fees from Gilead Sciences (the manufacturer of tenofovir disoproxil fumarate) and is the principal investigator of a phase IV study, sponsored by Gilead Sciences, of renal toxicities associated with antiretroviral therapies.
Gupta SK. Can the SMART Study Data Be Used to Assess Risk Factors for Renal Disease?. Ann Intern Med. 2009;150:282. doi: https://doi.org/10.7326/0003-4819-150-4-200902170-00018
Download citation file:
Published: Ann Intern Med. 2009;150(4):282.
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use